Biotech Values

[DewDiligence]

MRNA expects $19-22B of 2022 Spikevax sales:

https://www.accesswire.com/690184/Moderna-Reports-Fourth-Quarter-and-Fiscal-Year-2021-Financial-Results-and-Provides-Business-Updates

• Full year 2021 revenues of $18.5 billion; GAAP net-income of $12.2 billion and GAAP diluted EPS of $28.29

• Moderna increased its 2022 signed advance purchase agreements to approximately $19 billion, with additional signed options of approximately $3 billion; numerous discussions ongoing with governments for the fall of 2022 and 2023

• Moderna received full U.S. FDA approval for COVID-19 vaccine, Spikevax

• Moderna announces new bivalent booster candidate (mRNA-1273.214) combining Omicron-specific booster candidate (mRNA-1273.529) and the Moderna COVID-19 vaccine (mRNA-1273)

• Moderna announces a new $3 billion share repurchase plan

The $3B repurchase makes sense given the recent swoon in the share price and the ~$18B cash balance at 12/31/21.